MedPath

Clinical Trial News

SeaStar Medical Receives FDA Breakthrough Device Designation for Novel Therapy

SeaStar Medical has been granted a Breakthrough Device Designation by the FDA for its Selective Cytopheretic Device (SCD), aimed at treating acute kidney injury (AKI) in adults. This designation facilitates an expedited regulatory review for the upcoming pivotal clinical trial of the SCD, which targets hyperinflammation by selectively addressing activated neutrophils and monocytes.

FDA Grants Breakthrough Therapy Designation to Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer

  • The FDA has granted breakthrough therapy designation to trastuzumab deruxtecan (Enhertu) for treating adults with unresectable or metastatic HER2-low breast cancer who have received prior systemic therapy.
  • The designation is based on results from the phase 3 DESTINY-Breast04 trial, which demonstrated significant improvements in progression-free survival and overall survival in this patient population.
  • This represents the first trial to show that HER2-directed therapy can benefit patients with HER2-low expression, potentially changing diagnostic and treatment paradigms for breast cancer.
  • The multicenter study enrolled 557 patients with HER2-low breast cancer, randomizing them 2:1 to receive either trastuzumab deruxtecan or physician's choice of chemotherapy.

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

NCT03734029Active, Not RecruitingPhase 3
Daiichi Sankyo
Posted 12/27/2018

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

NCT03529110Active, Not RecruitingPhase 3
Daiichi Sankyo
Posted 8/9/2018

Six-Monthly Injection Shows Promise as Alternative to Daily Blood Pressure Medication in Global Trial

  • Queen Mary University of London is leading a global trial testing a six-monthly injection as an alternative to daily blood pressure tablets for hypertension treatment.
  • The study involves 630 patients worldwide, including 100 from the UK, and is funded by Alnylam Pharmaceuticals with support from the National Institute for Health and Care Research.
  • Researchers hope the subcutaneous injection could provide a more convenient treatment option for the estimated one-third of UK adults who have high blood pressure.
  • If successful, the treatment could offer significant benefits for patients who currently require daily medication to reduce their risk of heart attacks and strokes.

Dual-Targeting CAR-T Therapies Show Promise in Overcoming B-Cell Cancer Treatment Resistance

CAR-T
  • Researchers at University Hospitals Seidman Cancer Center developed a novel BAFF CAR-T therapy that targets three receptors (BAFF-R, BCMA, TACI) instead of one, potentially reducing antigen escape seen in CD19-only therapies.
  • A separate bispecific CAR-T therapy (LV20.19) targeting both CD20 and CD19 achieved a 90% overall response rate in a phase 1/2 trial for relapsed/refractory B-cell non-Hodgkin lymphoma.
  • The BAFF CAR-T approach may cause less severe B-cell aplasia compared to CD19 therapies since BAFF receptors are not expressed by early-stage B-cells.
  • Both therapies represent significant advances in addressing treatment resistance and improving outcomes for patients with B-cell malignancies.

Current Clinical Trials in Traumatic Brain Injury

A comprehensive review of clinical trials for traumatic brain injury (TBI) highlights the ongoing search for effective treatments, focusing on drugs like amantadine, botulinum toxin A, and tranexamic acid. Despite numerous trials, the variability in study outcomes underscores the need for careful trial design and patient stratification.

Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury

NCT04280965CompletedEarly Phase 1
The University of Texas Health Science Center at San Antonio
Posted 2/1/2019

Resuscitative Endocrinology:Single-dose Clinical Uses for Estrogen-Traumatic Brain Injury

NCT00973674CompletedPhase 2
University of Texas Southwestern Medical Center
Posted 7/1/2009

Adjunctive Pregnenolone in Veterans With Mild TBI

NCT00623506CompletedNot Applicable
Durham VA Medical Center
Posted 1/1/2008

Effect of Progesterone Therapy on Traumatic Subarachinoid Haemorrhage on Clinical Outcome and Resistive Vasculer Indices of Middle Cerebral Artery Transcranial Doppler

NCT04426487Unknown StatusEarly Phase 1
Minia University
Posted 6/20/2020

Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI

NCT01750268CompletedPhase 4
University of California, San Francisco
Posted 11/1/2012

Allopregnanolone for the Treatment of Traumatic Brain Injury

NCT01673828CompletedPhase 2
Michael A. Rogawski, MD, PhD
Posted 4/1/2013

Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)

NCT00453921CompletedNot Applicable
Dartmouth-Hitchcock Medical Center
Posted 2/1/2007

Dexamethasone for the Treatment of Vasogenic Pericontusional Edema.

NCT04303065Unknown StatusPhase 3
Hospital Son Espases
Posted 7/24/2020

Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression

NCT01821690RecruitingNot Applicable
Indiana University
Posted 5/15/2013

Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)

NCT01014403CompletedPhase 1
University of Texas Southwestern Medical Center
Posted 11/1/2009

Buspirone and Melatonin for Depression Following Traumatic Brain Injury

NCT04400266RecruitingPhase 4
Massachusetts General Hospital
Posted 8/1/2020

MLC901 for Moderate to Severe Traumatic Brain Injury (Specified Drug Code)

NCT04487275Unknown StatusPhase 4
Ali Amini Harandi
Posted 8/20/2018

Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury

NCT02990091WithdrawnPhase 2
University of Pennsylvania
Posted 1/1/2017

Propranolol Versus Propranolol and Clonidine in Sympathetic Hyperactivity After Moderate Traumatic Brain Injury

NCT04833218Unknown StatusEarly Phase 1
Minia University
Posted 1/31/2020

A First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers

NCT05033444CompletedPhase 1
Odyssey Group International, Inc.
Posted 2/9/2022

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children

NCT02712996CompletedPhase 4
Vanderbilt University
Posted 2/6/2017

Could Early Atorvastatin Offer Anti Inflammatory Effects Upon Brain in Traumatic Head Injury?

NCT04718155CompletedNot Applicable
Assiut University
Posted 3/1/2021

Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents

NCT02404779Unknown StatusPhase 4
University Hospital, Clermont-Ferrand
Posted 3/19/2015

Prehospital Tranexamic Acid Use for Traumatic Brain Injury

NCT01990768CompletedPhase 2
University of Washington
Posted 5/1/2015

Treatment Strategy for Alcohol Use Disorders in Veterans With TBI

NCT01342549CompletedPhase 3
VA Office of Research and Development
Posted 9/1/2011

Hyperbaric Oxygen Brain Injury Treatment Trial

NCT02407028RecruitingPhase 2
Hennepin Healthcare Research Institute
Posted 6/25/2018

Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury

NCT03061565Completed
Australian and New Zealand Intensive Care Research Centre
Posted 8/1/2017

Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury

NCT02240589CompletedNot Applicable
Indiana University
Posted 12/1/2014

Ketamine in Acute Brain Injury Patients.

NCT05097261RecruitingPhase 4
Geert Meyfroidt, MD, PhD
Posted 9/6/2021

Anterior Pituitary Hormone Replacement in Traumatic Brain Injury

NCT00957671CompletedPhase 4
The University of Texas Medical Branch, Galveston
Posted 11/1/2003

Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness

NCT03814356Active, Not RecruitingPhase 1
Massachusetts General Hospital
Posted 8/24/2020

Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness

NCT02025439CompletedNot Applicable
Edward Hines Jr. VA Hospital
Posted 2/1/2014

Exploring the Utility of [18F]3F4AP for Demyelination Imaging in Controls, Neurodegeneration and Traumatic Brian Injury

NCT04710550Active, Not RecruitingPhase 1
Massachusetts General Hospital
Posted 1/25/2021

Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI

NCT04550377RecruitingPhase 2
NYU Langone Health
Posted 5/26/2021

Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy

NCT03554265CompletedPhase 3
The University of Texas Medical Branch, Galveston
Posted 8/6/2018

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

NCT04099667Active, Not RecruitingPhase 2
Supernus Pharmaceuticals, Inc.
Posted 12/17/2019

Study on Cerebral Protection of Dexmedetomidine for Patients With Traumatic Brain Injury

NCT04006054Unknown StatusPhase 4
Xiangya Hospital of Central South University
Posted 6/6/2019

N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI

NCT02791945CompletedPhase 2
University of California, San Francisco
Posted 8/1/2016

Impact of Amantadine on Traumatic Brain Injury

NCT04527289CompletedPhase 4
Damanhour University
Posted 9/30/2020

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

NCT03992404Active, Not RecruitingPhase 3
Merz Pharmaceuticals GmbH
Posted 9/16/2019

Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury

NCT00704379CompletedPhase 2
Baylor College of Medicine
Posted 6/1/2008

The NIPA Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients

NCT05008926RecruitingPhase 3
University Hospital, Brest
Posted 3/15/2022

Hyperbaric Oxygen Therapy (HBO2) for Persistent Post-concussive Symptoms After Mild Traumatic Brain Injury (mTBI)

NCT01306968CompletedPhase 2
U.S. Army Medical Research and Development Command
Posted 2/1/2011

PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)

NCT03559114RecruitingPhase 3
Sunnybrook Health Sciences Centre
Posted 7/19/2018

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury

NCT03095066CompletedPhase 2
Otsuka Pharmaceutical Development & Commercialization, Inc.
Posted 5/30/2017

Ghrelin (OXE--103) for Acute Concussion Management

NCT04558346CompletedPhase 2
Michael Rippee
Posted 10/20/2020

Multicenter Evaluation of Memory Remediation After TBI With Donepezil

NCT02255799CompletedPhase 3
Baylor College of Medicine
Posted 9/1/2013

Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions

NCT01368432CompletedPhase 2
Johns Hopkins University
Posted 4/1/2010

Levetiracetam to Prevent Post-Traumatic Epilepsy

NCT01463033CompletedPhase 2
Pavel Klein
Posted 4/1/2005

The Influence of Noradrenaline on Coagulation and Fibrinolysis in Severe Isolated Brain Injury

NCT04515420Unknown Status
University Medical Centre Ljubljana
Posted 9/1/2020

Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI

NCT01670526CompletedPhase 3
VA Office of Research and Development
Posted 12/1/2012

Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics

NCT04499755RecruitingPhase 3
Sherief Abd-Elsalam
Posted 6/1/2020

Aerosolized Endotracheal Lidocaine to Avoid Intracranial Pressure Spikes in Patients With Severe Traumatic Brain Injury

NCT05058677RecruitingPhase 4
The University of Texas Health Science Center, Houston
Posted 11/9/2021

Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study

NCT00779324CompletedNot Applicable
Wake Forest University Health Sciences
Posted 8/1/2009

International Trial of Efficacy of Cytoflavin in Head Trauma

NCT04631484CompletedPhase 3
POLYSAN Scientific & Technological Pharmaceutical Company
Posted 11/22/2020

Early Propranolol After Traumatic Brain Injury: Phase II

NCT01202110TerminatedPhase 2
Cedars-Sinai Medical Center
Posted 6/1/2010

Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury in Older Adults

NCT04521881RecruitingPhase 3
London School of Hygiene and Tropical Medicine
Posted 4/18/2021

Biperiden Trial for Epilepsy Prevention

NCT04945213RecruitingPhase 3
Hospital Sirio-Libanes
Posted 1/10/2023

Beta Blocker Use In Traumatic Brain Injury Based On The High-Sensitive Troponin T Status

NCT04508244RecruitingPhase 4
Hamad Medical Corporation
Posted 12/29/2020

Allopregnanolone in Chronic Complex Traumatic Brain Injury

NCT04003285Not Yet RecruitingPhase 2
VA Office of Research and Development
Posted 9/1/2024

CLINICAL EFFECT OF BOTULINUM TOXIN TYPE A IN TREATMENT OF SPASTICITY

NCT04673240Unknown Status
Università degli Studi del Piemonte Orientale "Amedeo Avogadro"
Posted 3/29/2019

Controlling Hyperadrenergic Activity in Neurologic Injury

NCT01343329WithdrawnPhase 1
Johns Hopkins University
Posted 7/1/2011

The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury

NCT05095857RecruitingPhase 4
Rigshospitalet, Denmark
Posted 9/15/2023

Dysport® Adult Lower Limb Spasticity Study

NCT01249404CompletedPhase 3
Ipsen
Posted 3/1/2011

CDP-Choline and Working Memory After TBI: A Neuroimaging Study

NCT00727246CompletedPhase 2
Patricia M. Arenth
Posted 3/1/2009

Phase 2 a Study to Assess Safety and Pharmacokinetics of VAS203 in Patients With Traumatic Brain Injury

NCT02012582CompletedPhase 2
veriNOS operations GmbH
Posted 11/1/2009

Dysport® Adult Upper Limb Spasticity

NCT01313299CompletedPhase 3
Ipsen
Posted 8/1/2011

ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion

NCT04744051Active, Not RecruitingPhase 1
American CryoStem Corporation
Posted 2/1/2021

Inhaled Nitric Oxide in Brain Injury

NCT03260569CompletedPhase 3
University of Cincinnati
Posted 12/12/2018

Changes in Glutamatergic Neurotransmission of Severe TBI Patients

NCT04244058SuspendedEarly Phase 1
Weill Medical College of Cornell University
Posted 9/23/2020

Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI)

NCT00970944CompletedPhase 2
JFK Medical Center
Posted 2/1/2003

Pharmacological Management of Seizures Post Traumatic Brain Injury

NCT04573803Not Yet RecruitingPhase 3
Cambridge University Hospitals NHS Foundation Trust
Posted 3/1/2021

DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury

NCT01322048CompletedPhase 2
Vanderbilt University
Posted 8/1/2011

Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)

NCT00702364CompletedNot Applicable
Craig Hospital
Posted 1/1/2008

ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients

NCT04588311RecruitingPhase 3
Australian and New Zealand Intensive Care Research Centre
Posted 11/9/2020

Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression

NCT00621751CompletedNot Applicable
Wake Forest University Health Sciences
Posted 2/1/2008

Ketogenic Diet for Traumatic Brain Injury

NCT03982602CompletedEarly Phase 1
University of Missouri-Columbia
Posted 7/4/2019

mTBI Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms

NCT01611194CompletedPhase 2
U.S. Army Medical Research and Development Command
Posted 9/11/2012

Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury

NCT01322009CompletedPhase 1
University of Pittsburgh
Posted 3/1/2011

Neuroactive Steroids and Traumatic Brain Injury (TBI) in OEF/OIF Veterans

NCT01336413CompletedPhase 2
VA Office of Research and Development
Posted 10/1/2013

Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

NCT04867317RecruitingPhase 3
VA Office of Research and Development
Posted 1/13/2025

Use of Biperiden for the Prevention of Post-traumatic Epilepsy

NCT01048138TerminatedPhase 3
Federal University of São Paulo
Posted 1/31/2018

Hyperbaric Treatment of Traumatic Brain Injury (TBI)

NCT01847755CompletedPhase 1
Barry Miskin, MD
Posted 4/1/2013

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

NCT04815967Active, Not RecruitingPhase 2
Supernus Pharmaceuticals, Inc.
Posted 11/16/2021

Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury

NCT00313716CompletedPhase 2
Claudia Sue Robertson
Posted 4/1/2006

Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: an Efficacy Study

NCT04387305Not Yet RecruitingPhase 3
Daniel Nishijima, MD, MAS
Posted 10/1/2025

Treatment of Spontaneous Hyperventilation With Remifentanil in Traumatic Brain Injury Patients

NCT04974060Unknown StatusNot Applicable
Capital Medical University
Posted 6/1/2021

Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients

NCT00795366CompletedNot Applicable
University of Miami
Posted 9/1/2008

Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic Brain Injury

NCT04489160Unknown StatusPhase 2
Leiden University Medical Center
Posted 2/25/2021

Antisecretory Factor In Severe Traumatic Brain Injury

NCT04117672RecruitingPhase 2
Peter Siesjö
Posted 3/10/2020

Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention

NCT00618436CompletedPhase 4
University of Cincinnati
Posted 8/1/2007

Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.

NCT00766038CompletedPhase 2
University of Pennsylvania
Posted 9/1/2008

Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

NCT05049057RecruitingPhase 2
Henry M. Jackson Foundation for the Advancement of Military Medicine
Posted 7/19/2022

Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI

NCT02225106CompletedPhase 2
University of Pennsylvania
Posted 8/6/2014

Treatment of Post-Traumatic Brain Injury (TBI) Depression

NCT00233103CompletedPhase 2
Icahn School of Medicine at Mount Sinai
Posted 6/1/2003

Valproate for Mood Swings and Alcohol Use Following Head Injury

NCT01760785CompletedNot Applicable
University of Colorado, Denver
Posted 9/1/2008

Cerebrovascular Reactivity in American Football Players

NCT03417492TerminatedPhase 1
University of Pennsylvania
Posted 3/1/2018

Beta Blockade in in Traumatic Brain Injury

NCT02957331CompletedPhase 4
University of Tennessee
Posted 1/1/2016

Amitriptyline to Prevent Headache After Traumatic Brain Injury

NCT01856270CompletedPhase 2
University of Washington
Posted 4/1/2013

Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy

NCT01201863CompletedPhase 4
Craig Hospital
Posted 9/1/2010

Methylphenidate for Attention Problems After Pediatric TBI

NCT01933217CompletedPhase 4
Children's Hospital Medical Center, Cincinnati
Posted 11/1/2013

Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness

NCT04427241Not Yet RecruitingPhase 4
Konkuk University Medical Center
Posted 6/1/2023

Sumatriptan as Treatment for Post-traumatic Headache

NCT01854385CompletedPhase 2
University of Washington
Posted 6/1/2013

Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability

NCT02270736CompletedPhase 3
Merz Pharmaceuticals GmbH
Posted 2/9/2015

Diet and Gut Microbiota Shape Development of Regulatory T Cells, Study Finds

  • Research reveals that diet and gut microbiota significantly influence the development of regulatory T cells (Tregs), which are crucial for immune tolerance and preventing autoimmune diseases.
  • Both dietary components and bacterial metabolites can regulate Treg differentiation through multiple mechanisms, including epigenetic changes, metabolic alterations, and receptor engagement.
  • Western diets may contribute to inflammatory diseases by disrupting normal Treg development, while dietary interventions could potentially restore Treg numbers to prevent or treat these conditions.

Novel Therapies Transform Multiple Myeloma Treatment Landscape: CAR-T, Bispecifics Lead Innovation Wave

  • Recent FDA approvals including CAR-T cell therapies ide-cel and cilta-cel, along with antibody-drug conjugate belantamab mafodotin, have significantly expanded treatment options for multiple myeloma patients.
  • Despite progress extending median survival from 2-3 years to 10-15 years, challenges remain in managing drug resistance and relapse, with emerging CELMoD oral therapies showing promise for outpatient treatment.
  • Dr. Paul Richardson highlights the strategic importance of early treatment decisions and the need for practical, community-based delivery options, particularly during the COVID-19 pandemic.

FDA Approves Sotorasib for KRAS G12C Mutated Metastatic NSCLC

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sotorasib (Lumakras™, Amgen) for the treatment of adults with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have received at least one prior systemic therapy. This approval is based on the results of the CodeBreaK 100 trial, showing an overall response rate of 36% among patients treated with sotorasib.

FDA Extends Review of Regeneron's REGEN-COV for COVID-19 Treatment and Prophylaxis

• The FDA has extended the review of Regeneron's BLA for REGEN-COV by three months, with a new target action date of July 13, 2022. • The extension is due to ongoing discussions with the FDA regarding pre-exposure prophylactic use, supported by additional data from a completed prophylaxis trial. • REGEN-COV is currently not authorized for use in any U.S. states, territories, or jurisdictions due to variant susceptibility. • Regeneron is developing next-generation antibodies active against current variants of concern and has initiated a first-in-human clinical trial.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.